The interim results of a randomised comparison between indomethacin and paracetamol in covid-19 showed stark differences in efficacy, confirming the positive results of early trials of indomethacin. IMI… read more.
Pfizer Inc. announced that the FDA has approved Ticovac (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. Ticovac… read more.
Innovators at Purdue University and Houston Methodist Research Institute have created a novel strategy for developing an effective vaccine for a widespread form of tuberculosis. Mycobacterium tuberculosis (Mtb)… read more.
Moderna, Inc. announced that the Therapeutic Goods Administration (TGA) has granted provisional registration to the COVID-19 Vaccine Moderna in Australia for active immunization to prevent COVID-19 caused by… read more.
The results of the ivermectin meta-analysis could have important implications for health policy. Dr Edmund Fordham, one of the co-authors of the review, describes how the findings could… read more.
The methodological approach to the ivermectin meta-analysis provides further reassurance of the robustness of the findings. Mr Andrew Bryant and Dr Edmund Fordham describe some of the critical… read more.
The Bryant-Lawrie meta-analysis included only randomised controlled trials (RCTs) but evidence from observational trials and real world experience sheds further light on the effectiveness of ivermectin, according to… read more.
June 2021 saw the publication of the systematic review and meta-analysis of randomised controlled trials of ivermectin for treatment and prophylaxis of covid-19 undertaken by Dr Tess Lawrie’s… read more.
Rates of the very rare clotting disorder, thrombosis with thrombocytopenia syndrome (TTS), following a second dose of Vaxzevria are comparable to the background rate in an unvaccinated population… read more.
Interim results from a Phase 1/IIa sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by… read more.
Gilead Sciences, Inc. announced a pooled analysis of a 48-week open-label extension of two Phase III studies (Study 1489 and Study 1490) shows 99% of participants who initiated… read more.
IMI has been reporting on ivermectin since December 2020, keeping our readers and viewers up-to-date with research and practice developments. To mark World Ivermectin Day (24th July 2021),… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
